Pipeline Insight: Acute Stroke - Considerable unmet need is balanced by substantial commercial risk

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2006-03-31

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Stroke is one of the top three causes of death and its incidence in the seven major markets is expected to increase in the next ten years because of an aging population. Long term disability caused by stroke is a major economic burden on healthcare systems, current treatment options are limited and general awareness of stroke is poor.


Scope

  • Assessment of the patient potential for developmental agents in the setting of acute stroke over the period 2006-15
  • Overview of the acute stroke R&D pipeline, with detailed information on the classes in development, comparator drugs and trial design features
  • Commercial analysis of key agents in development in terms of their ability to satisfy key unmet needs, supported by the views of key opinion leaders
  • Sales forecasts for key late-stage developmental acute stroke drugs in the seven major markets to 2015


    • Report Highlights
    In the setting of acute stroke, a patient's treatment options and recovery prospects are a function of time. Therefore any delay related to the time-to-treatment constitutes a resistor to market entry and uptake for stroke therapies in the acute care hospital setting.

    The unmet in the setting of acute hemorrhagic stroke is high for hemostatic agents whose action is immediate, short lasting and localized to the site of vascular injury. However, despite the great extent of unmet need in this setting, stroke physicians are concerned with the cost of therapy.

    Since stroke is a vascular condition that precipitates neurological damage, there is a need for non-causative therapies addressing the neurological aspect of the condition. However, in order to experience satisfactory market penetration, developmental neuroprotective agents will have to show compatibility with current reperfusion therapies.


    Reasons to Purchase

  • Understand the key factors that will contribute to the success of the next generation of acute stroke drugs
  • View independent sales forecasts for products in late stage development for therapy of acute stroke
  • Understand physician sentiment on clinical trial endpoints and late stage candidate drugs for the stroke market

    • Table of Contents

    Other users found this report page using the following search terms: stroke neuroprotection stroke edavarone pipeline unmet need 2008 market clinical acute swot

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.